Article thumbnail

Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression

By Michele L. Pucak, Katherine A. L. Carroll, Douglas A. Kerr and Adam L. Kaplin

Abstract

Evidence suggests that depression in multiple sclerosis (MS) is largely biologically mediated by some of the same processes involved in the immunopathogenesis of this neurologic disease. In particular, the increase in proinflammatory cytokines, activation of the hypothalamic-pituitary-adrenal (HPA) axis, and reduction in neurotrophic factors that occur in MS may each account for the increased rate of depression seen in MS. The possible contributions of these neuroinflammatory, neuroendocrine, and neurotrophic mechanisms suggest a diverse array of novel treatment strategies for depression, both in the context of inflammatory conditions as well as in idiopathic depression. Furthermore, if such processes in MS play a causative role in the pathogenesis of depression, and depression in turn has affects on neuro-physiological processes related to immune function, then treatment of depression might have a positive effect on MS disease progression. This makes treating MS depression a neuropsychiatric imperative

Topics: Translational Research
Publisher: Les Laboratoires Servier
OAI identifier: oai:pubmedcentral.nih.gov:3181849
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1999). A multidimensional assessment of multiple sclerosis: relationships between disability domains. Acta Neurol Scand.
  2. A neurotrophic model for stress-related mood disorders. Biol Psychiatry.
  3. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferongamma in mice.
  4. (1992). A prospective study of depression and immune dysregulation in multiple sclerosis. Arch Neurol.
  5. (2006). A temporal framework for understanding the effects of stressful life events on inflammation in patients with multiple sclerosis. Brain Behav Immun.
  6. Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression.
  7. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects.
  8. Adult neurogenesis and neural stem cells of the central nervous system in mammals.
  9. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants.
  10. (2006). Ankerst DP. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res.
  11. (1994). Anti-glucocorticoid effects of dehydroepiandrosterone (DHEA). Mol Cell Biochem.
  12. Antidepressants alter cell proliferation in the adult brain in vivo and in neural cultures in vitro.
  13. (2007). Antidepressants attenuate increased susceptibility to colitis in a murine model of depression.
  14. Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology. 1997;22(suppl 1):S125-S132.
  15. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry.
  16. Association between depression and elevated C-reactive protein. Psychosom Med.
  17. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis.
  18. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.
  19. (2006). Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry.
  20. Behavioral implications of lowering cholesterol levels: a double-blind pilot study.
  21. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus.
  22. Brain-derived neurotrophic factor in patients with multiple sclerosis.
  23. Brain-derived tumor necrosis factor-alpha and its involvement in noradrenergic neuron functioning involved in the mechanism of action of an antidepressant.
  24. Cause of death in patients attending multiple sclerosis clinics.
  25. Cerebrospinal cytokine levels in patients with acute depression.
  26. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus.
  27. (2001). Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl).
  28. Clinical and biological effects of mifepristone treatment for psychotic depression.
  29. Clinical depression and inflammatory risk markers for coronary heart disease.
  30. Controlling inflammation: the cholinergic antiinflammatory pathway. Biochem Soc Trans.
  31. Cortical lesions and brain atrophy in MS.
  32. Corticosteroid-induced psychotic and mood disorders: diagnosis defined by DSM-IV and clinical pictures.
  33. (2006). Corticotropin-releasing hormone receptor antagonists.
  34. Cortisol secretion and dexamethasone response in depression.
  35. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia.
  36. Cytokine production and treatment response in major depressive disorder.
  37. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry.
  38. (2005). Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des.
  39. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev.
  40. Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects.
  41. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med.
  42. (1992). Depression and immunocompetence: a review of the literature. Psychol Bull.
  43. Depression and multiple sclerosis.
  44. Depression and quality of life in multiple sclerosis.
  45. Depression during exacerbations in multiple sclerosis: the importance of uncertainty. Mult Scler.
  46. Depression in multiple sclerosis: a review.
  47. (1997). Depression in multiple sclerosis. Psychother Psychosom.
  48. Depression in persons with multiple sclerosis.
  49. (1983). Disease activity and emotional state in multiple sclerosis. Ann Neurol.
  50. Double-blind treatment of major depression with dehydroepiandrosterone.
  51. (2005). Drug Insight: using statins to treat neuroinflammatory disease. Nat Clin Pract Neurol.
  52. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study.
  53. (1988). Effect of ketoconazole on a hypophysectomized, hypercortisolemic, psychotically depressed woman. Arch Gen Psychiatry.
  54. Effects of antidepressants on the production of cytokines.
  55. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter.
  56. (1999). Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry.
  57. Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b.
  58. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov.
  59. Enhanced BDNF signaling is associated with an antidepressant-like behavioral response and changes in brain monoamines.
  60. Enhancement of hippocampal neurogenesis by lithium.
  61. Enriched environment and physical activity stimulate hippocampal but not olfactory bulb neurogenesis.
  62. Essential role of brainderived neurotrophic factor in adult hippocampal function.
  63. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry.
  64. (1995). Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry.
  65. Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis.
  66. Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis.
  67. Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality.
  68. (1985). Failure to normalize the dexamethasone suppression test: association with length of illness. Biol Psychiatry.
  69. Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone. Mult Scler.
  70. Fluoxetine up-regulates expression of cellular FLICE-inhibitory protein and inhibits LPS-induced apoptosis in hippocampus-derived neural stem cell.
  71. (2007). Glatiramer acetate could be a potential antidepressant through its neuroprotective and anti-inflammatory effects. Med Hypotheses.
  72. (2001). Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry.
  73. Group. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler.
  74. (1996). Hippocampal atrophy in recurrent major depression.
  75. Hippocampal mossy fiber sprouting induced by chronic electroconvulsive seizures.
  76. Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis.
  77. IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles.
  78. (1998). IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int Immunol.
  79. Immune activation and depression in women with rheumatoid arthritis.
  80. Immune dysregulation in major depression: a critical review of existing evidence.
  81. (1995). Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol. Eur Arch Psychiatry Clin Neurosci.
  82. In search of a conceptualization of multiple sclerosis: a historical perspective. Neuropsychol Rev.
  83. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system.
  84. (2001). Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry.
  85. Increased neurogenesis in a model of electroconvulsive therapy.
  86. (1996). Indicators of immune activation in major depression. Psychiatry Res.
  87. Inflammatory blockade restores adult hippocampal neurogenesis.
  88. (2005). Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function. Mol Psychiatry.
  89. (1995). Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial.
  90. (1999). Interleukin-1 beta production in dysthymia before and after pharmacotherapy. Biol Psychiatry.
  91. (1997). Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci.
  92. Investigation of cytokine (tumor necrosis factor-alpha, interleukin-6, interleukin-10) concentrations in the cerebrospinal fluid of female patients with multiple sclerosis and systemic lupus erythematosus.
  93. (2004). Is impaired neurogenesis relevant to the affective symptoms of depression? Biol Psychiatry.
  94. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis.
  95. Lipid-lowering drugs and the risk of depression and suicidal behavior.
  96. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology (Berl).
  97. Long-term statin use and psychological well-being.
  98. (1991). Loss of glucocorticoid fast feedback in depression. Arch Gen Psychiatry.
  99. Magnetic resonance spectroscopy of memory and frontal brain region in early multiple sclerosis.
  100. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis.
  101. Metabolite changes in normalappearing gray and white matter are linked with disability in early primary progressive multiple sclerosis.
  102. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry.
  103. Mild depressive symptoms are associated with amplified and prolonged inflammatory responses after influenza virus vaccination in older adults. Arch Gen Psychiatry.
  104. (1996). modulates interleukin-1-and stress-induced activation of the hypothalamic-pituitary-adrenal axis in male rats.
  105. (1998). Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. Arch Neurol.
  106. MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine.
  107. Multiple sclerosis, depression, and the risk of suicide.
  108. Multiple sclerosis, interferon beta1b and depression. A prospective investigation.
  109. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.
  110. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis.
  111. Neuronal birth and death.
  112. (2007). Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin.
  113. Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis.
  114. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clin Immunol.
  115. Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode.
  116. (1984). Persistent neuroendocrine dysregulation in major depressive disorder: a marker for early relapse. Biol Psychiatry.
  117. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change.
  118. Predictors of dyadic adjustment in multiple sclerosis. Mult Scler.
  119. Prevalence of depressive disorders and change over time in late-stage ALS.
  120. (1998). Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress.
  121. Psychiatric side effects of interferonbeta in multiple sclerosis. Eur Psychiatry.
  122. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis.
  123. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6.
  124. (1995). Regulation of the human serotonin transporter by interleukin-1 beta.
  125. (1993). Relationships between interleukin6 activity, acute phase proteins, and function of the hypothalamic-pituitaryadrenal axis in severe depression. Psychiatry Res.
  126. (1993). Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res.
  127. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants.
  128. (1992). Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol.
  129. Role of cytokines in neurological disorders.
  130. Role of neurotrophic factors in depression.
  131. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy.
  132. Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis.
  133. Steroid psychosis: a review. Gen Hosp Psychiatry.
  134. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine.
  135. Structural brain abnormalities in multiple sclerosis patients with major depression.
  136. Structural brain correlates of emotional disorder in multiple sclerosis.
  137. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus.
  138. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action.
  139. Thalamic neurodegeneration in multiple sclerosis.
  140. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a doubleblind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry.
  141. The EAE-associated behavioral syndrome: I. Temporal correlation with inflammatory mediators.
  142. The EAE-associated behavioral syndrome: II. Modulation by anti-inflammatory treatments.
  143. (1998). The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety.
  144. The extracelular signal-related kinase pathway: an emerging promising target for mood stabilizers. Curr Opin Psychiatry.
  145. The genetics of depression: a review. Biol Psychiatry.
  146. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation.
  147. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice.
  148. The immunoregulatory effects of antidepressants.
  149. (1991). The macrophage theory of depression. Med Hypotheses.
  150. The neuropsychiatry of multiple sclerosis.
  151. (2006). The neuropsychological profile of psychotic major depression and its relation to cortisol. Biol Psychiatry.
  152. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity.
  153. (2005). The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler.
  154. (1993). The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. Ciba Found Symp.
  155. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression.
  156. The role of stress-response systems for the pathogenesis and progression of MS. Trends Immunol.
  157. Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis.
  158. Tryptophan depletion and its implications for psychiatry.
  159. Unkind cytokines: current evidence for the potential role of cytokines in immune-mediated depression. Int Rev Psychiatry.
  160. Unrecognised symptoms of depression in a community-based population with multiple sclerosis.
  161. Untreated depression and hippocampal volume loss.
  162. Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin6 treatment.
  163. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders.